Vimarsana
Biggest News Aggregation in the World

Page 6 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference - Vimarsana News

STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference

/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies...

Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 ... - Vimarsana News

Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 ...

JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition - Vimarsana News

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies...

Crossbow Therapeutics' novel antibody therapies financed with $80 million Series A - Vimarsana News

Crossbow Therapeutics' novel antibody therapies financed with $80 million Series A

Crossbow Therapeutics, a biotech company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced a $80 million Series A funding round.

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class ... - Vimarsana News

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class ...

Proprietary T-Bolt™ technology dramaticallybroadens the benefits of immunotherapy by targeting the entire universe of cancer antigens